Blue Spark Technologies Announces Observational Trial Using TempTraq® Wearable Device in CAR T Patient Monitoring
CLEVELAND--(BUSINESS WIRE)--May 19, 2021--
Blue Spark Technologies, Inc. today announced that Bristol Myers Squibb (BMS, NYSE: BMY) will use its TempTraq wearable Bluetooth continuous body temperature monitoring platform in a U.S. observational trial to monitor patients across multiple BMS CAR T assets prior to and following CAR T patients’ infusion with the cell therapy. This observational trial will be Bristol Myers Squibb’s first use of a remote patient monitoring technology to track CAR T patient temperatures, which can be a sign of cytokine release syndrome (CRS), a common side effect observed within the CAR T category of therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005124/en/
Blue Spark Technologies' TempTraq® Wearable Wireless Thermometer (Photo: Business Wire)
In the partnership, Blue Spark Technologies will supply the TempTraq wearable device for use by patients with multiple myeloma or lymphoma who are participating in the observational trial to receive a Bristol Myers Squibb CAR T product. The trial represents a first step to explore how technologies like TempTraq, paired with clinical, disease state and scientific expertise can inform next-generation products aimed at supporting specific patient situations such as post-CAR T infusion.
In the observational trial, the innovative temperature technology will provide real-time, continuous temperature data to patients and their clinicians so they can co-monitor for fever, which is one of the early signs of CRS.
“As we progress into next-generation therapeutics like CAR T cell therapies, patient-centric technologies like TempTraq will become supportive components in creating an ecosystem where the promise of cell therapy can thrive,” said Sarah Hersey, vice president, Precision Medicine at Bristol Myers Squibb.
“We are honored that BMS has decided to partner with Blue Spark on this cutting-edge solution,” said John Gannon, Blue Spark President and Chief Executive Officer.
The TempTraq wearable device will be used at as many as 12 BMS cell therapy clinical trial sites across the U.S.
TempTraq®, Blue Spark Technologies’ patented innovation, is the only disposable Bluetooth®, wearable temperature monitor in the form of a soft, comfortable patch that continuously, safely and comfortably monitors body temperature for up to 72 hours and sends notifications to Apple® or Android™ compatible mobile devices.
TempTraq Connect is the HIPAA-compliant cloud service supported by Google Healthcare Cloud Platform that enables patients and caregivers to monitor body temperature from anywhere. It can also directly integrate with healthcare provider electronic medical record (EMR) systems and nurse monitoring stations, providing a secure method of storing patient healthcare data. The system is FDA, CE and TGA cleared.
For more information about TempTraq®, visit https://temptraq.healthcare.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210519005124/en/
CONTACT: Kristin Schaeffer
CG Life / TempTraq
KEYWORD: UNITED STATES NORTH AMERICA OHIO
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES
SOURCE: Blue Spark Technologies, Inc.
Copyright Business Wire 2021.
PUB: 05/19/2021 07:30 AM/DISC: 05/19/2021 07:32 AM